BCL2 and B-cell chronic lymphocytic leukemia: ABT-199 showed 100-fold increased selectivity for Bcl-2 over Bcl-xl or Bcl-w and it was found to be more effective against Chronic Lymphocytic Leukemia (CLL) with milder cases of thrombocytopenia [6].